Dyne Therapeutics' stock dropped 16% following Novartis' failure in a DM1 clinical trial, which increased concerns about the effectiveness of RNA-targeting therapies for muscle diseases. This setback challenges the potential of Dyne's lead drug, z-rostudirsen, especially regarding its long-term functional benefits despite likely FDA approval. Dyne remains financially strong with nearly $900 million in cash and a $3.9 billion enterprise value, supporting its ongoing Phase 3 trials. However, investor confidence has waned, applying a higher risk discount to Dyne's pipeline prospects.
WeShop Holdings Limited announced that eligible UK members can start claiming Class A ordinary shares on November 23, marking one year since its Nasdaq listing. Members earn WePoints through shopping, which can now be converted into company shares un...
Logile held its inaugural Connect EMEA event on October 14, 2026, gathering UK and EMEA retail leaders like bp, Booths, Co-op, and Morrisons to discuss integrating store planning with execution through AI-powered connected workforce solutions. The ev...
The global motorsports market is projected to grow from $11.45 billion in 2026 to $16.17 billion by 2031, with a CAGR of 7.15%. Growth is fueled by expanding digital rights, streaming platforms, and increased sponsorship opportunities, especially in ...
YYForce Inc. announced a new integrated platform that connects human expertise, AI, robotics, and IoT systems to enhance hotel operations. This platform aims to coordinate staffing, robotic tasks, and building performance, preparing the hospitality s...
YYForce Inc. announced its vision to develop an integrated platform that combines human expertise, AI, robotics, and IoT systems to support next-generation smart hotel operations. The platform aims to coordinate staffing, service delivery, robotic ta...
